Evidence map›Paper›PMID 22390944›Full record

ArticleNeuroscience2012

Orexinergic modulation of GABAergic neurotransmission to cardiac vagal neurons in the brain stem nucleus ambiguus changes during development.

O Dergacheva, R Bateman, P Byrne, D Mendelowitz

Open access · greenAbstract read
In one paragraph

Article in Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Cardiac vagal motor neurons.Current opinion in neurobiology · 2025
    Review
  2. Article
  3. Article
  4. Parasympathetic Vagal Control of Cardiac Function.Current hypertension reports · 2016
    Review
  5. Orexin/hypocretin receptor signalling cascades.British journal of pharmacology · 2014
    Review
  6. Article
  7. Article
  8. Article
  9. Orexin/Hypocretin Signaling.Current topics in behavioral neurosciences
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

O DergachevaDepartment of Pharmacology and Physiology, The George Washington University, 2300 Eye Street NW, Washington, D.C. 20037, USA. olgad@gwu.edu
R Bateman
P Byrne
D Mendelowitz
George Washington University · US

Funding

Nicotine Modulation of Parasympathetic Cardiac NeuronsR01HL072006 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI MENDELOWITZ, DAVID · 2003 to 2017
$5.4M
NEUROPHYSIOLOGY OF PARASYMPATHETIC CARDIAC NEURONSR01HL049965 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MENDELOWITZ, DAVID · 1998 to 2014
$4.6M
MECHANISM OF CARDIORESPIRATORY RHYTHM IN NEONATESR01HL059895 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MENDELOWITZ, DAVID · 1998 to 2013
$4.1M
NEUROPHYSIOLOGY OF PARASYMPATHETIC CARDIAC NEURONSR29HL049965 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MENDELOWITZ, DAVID · 1993 to 1997
–
NHLBI NIH HHS HL 49965NHLBI NIH HHS HL 59895NHLBI NIH HHS HL 72006NHLBI NIH HHS R01 HL049965NHLBI NIH HHS R01 HL059895NHLBI NIH HHS R01 HL072006
6 · The paper itself

Abstract

Cardiac vagal neurons (CVNs) in the nucleus ambiguus (NA) are the major determinant of parasympathetic activity to the heart. Spontaneous GABAergic neurotransmission to CVNs is modulated by hypothalamic neuropeptide orexin-A in postnatal days 2-5 (P5) rats; however, during early postnatal development, orexin expression changes, and the role of orexin-A in modulating CVN activity at other stages of development is unknown. In this study, we compared changes in GABAergic inhibitory postsynaptic currents (IPSCs) in CVNs evoked by orexin-A in P5, P16-20 (P20), and P27-30 (P30) rats using an in vitro brain stem slice preparation. Bath-applied orexin-A enhanced GABAergic IPSCs in all CVNs tested in P5 and P30 animals and in the majority of neurons tested in P20 pups. Focal application of orexin-A ejected from a pipette positioned within 30 μm of the patched CVN did not alter GABAergic signaling in P5 pups. In contrast, in both P20 and P30 rats, focal application of orexin-A inhibited GABAergic IPSCs, and this inhibition persisted in the presence of tetrodotoxin. These results indicate orexin-A facilitates GABAergic IPSCs likely by activating preceding GABAergic neurons that project to CVNs. Orexin-A also likely acts at GABAergic presynaptic terminals surrounding CVNs within the NA to inhibit GABA release. The latter mechanism is absent in P5 pups but occurs in P20 and P30 rats. In conclusion, this study elucidates an important maturation of the parasympathetic cardiac control system. Alterations in these developmental mechanisms may play a role in pathogenesis of disorders related to a specific stage of development maturation.

Indexed as

AnimalsBrain StemGABAergic NeuronsHeartInhibitory Postsynaptic PotentialsIntracellular Signaling Peptides and ProteinsNeuropeptidesOrexinsOrgan Culture TechniquesPatch-Clamp TechniquesRatsRats, Sprague-DawleySynaptic TransmissionVagus NerveIntracellular Signaling Peptides and ProteinsNeuropeptidesOrexins

Identifiers

PMID22390944
PMCPMC3352601
OpenAlexW2076918051

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.